Intravitreal Bevacizumab in Refractory Neovascular Glaucoma: A Prospective, Observational Case Series | Glaucoma | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Aiello  LPAvery  RLArrigg  PG  et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med 1994;331 (22) 1480- 1487PubMedGoogle Scholar
2.
Casey  RLi  WW Factors controlling ocular angiogenesis.  Am J Ophthalmol 1997;124 (4) 521- 529PubMedGoogle Scholar
3.
Tripathi  RCLi  JTripathi  BJChalam  KVAdamis  AP Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.  Ophthalmology 1998;105 (2) 232- 237PubMedGoogle Scholar
4.
Duker  JSBrown  GC The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction.  Ophthalmology 1989;96 (1) 92- 95PubMedGoogle Scholar
5.
Sivak-Callcott  JAO'Day  DMGass  JD  et al.  Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;1081767- 17771800PubMed
6.
Cashwell  LFMarks  WP Panretinal photocoagulation in the management of neovascular glaucoma.  South Med J 1988;81 (11) 1364- 1368PubMedGoogle Scholar
7.
Wand  M Treatment of neovascular glaucoma.  Ann Ophthalmol 1979;11 (10) 1557- 1559PubMedGoogle Scholar
8.
Ehlers  JPSpirn  MJLam  ASivalingam  ASamuel  MATasman  W Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma.  Retina 2008;28 (5) 696- 702PubMedGoogle Scholar
9.
Ferrara  NDamico  LShams  NLowman  HKim  R Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.  Retina 2006;26 (8) 859- 870PubMedGoogle Scholar
10.
Kim  YGHong  SLee  CS  et al.  Level of vascular endothelial growth factor in aqueous humor and surgical results of Ahmed glaucoma valve implantation in patients with neovascular glaucoma.  J Glaucoma 2009;18 (6) 443- 447PubMedGoogle Scholar
11.
Gartner  SHenkind  P Neovascularization of the iris (rubeosis iridis).  Surv Ophthalmol 1978;22 (5) 291- 312PubMedGoogle Scholar
12.
Günalp  IGündüz  KOzkan  M Causes of enucleation: a clinicopathological study.  Eur J Ophthalmol 1997;7 (3) 223- 228PubMedGoogle Scholar
13.
Wagner  ADArnold  DGrothey  AAHaerting  JUnverzagt  S Anti-angiogenic therapies for metastatic colorectal cancer.  Cochrane Database Syst Rev 2009; (3) CD005392PubMedGoogle Scholar
14.
Rich  RMRosenfeld  PJPuliafito  CA  et al.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.  Retina 2006;26 (5) 495- 511PubMedGoogle Scholar
15.
Cleary  CAJungkim  SRavikumar  KKelliher  CAcheson  RWHickey-Dwyer  M Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.  Eye (Lond) 2008;22 (1) 82- 86PubMedGoogle Scholar
16.
Iliev  MEDomig  DWolf-Schnurrbursch  UWolf  SSarra  GM Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.  Am J Ophthalmol 2006;142 (6) 1054- 1056PubMedGoogle Scholar
17.
Wakabayashi  TOshima  YSakaguchi  H  et al.  Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.  Ophthalmology 2008;115(9)1571- 1580Google Scholar
18.
Jonas  JBGolubkina  LLibondi  TRensch  F Intravitreal bevacizumab for neovascular glaucoma.  Acta Ophthalmol 2010;88 (2) e22- e23PubMedGoogle Scholar
19.
Moraczewski  ALLee  RKPalmberg  PFRosenfeld  PJFeuer  WJ Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.  Br J Ophthalmol 2009;93 (5) 589- 593PubMedGoogle Scholar
20.
Hansson  SO Uncertainty and the ethics of clinical trials.  Theor Med Bioeth 2006;27 (2) 149- 167PubMedGoogle Scholar
21.
Spratt  AOgunbowale  LFranks  W Bevacizumab: a compassionate way of doing business?  Eye (Lond) 2007;21 (6) 890- 891PubMedGoogle Scholar
22.
Abràmoff  MDRamos  LPJansen  GHMourits  MP Patients with persistent pain after enucleation studied by MRI dynamic color mapping and histopathology.  Invest Ophthalmol Vis Sci 2001;42 (10) 2188- 2192PubMedGoogle Scholar
23.
Weiss  DIGold  D Neofibrovascularization of iris and anterior chamber angle: a clinical classification.  Ann Ophthalmol 1978;10 (4) 488- 491PubMedGoogle Scholar
24.
Teich  SAWalsh  JB A grading system for iris neovascularization: prognostic implications for treatment.  Ophthalmology 1981;88 (11) 1102- 1106PubMedGoogle Scholar
25.
Holladay  JT Visual acuity measurements.  J Cataract Refract Surg 2004;30 (2) 287- 290PubMedGoogle Scholar
26.
dell’Omo  RKulkarni  AFranks  WA Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.  Acta Ophthalmol 2008;86 (6) 698- 700PubMedGoogle Scholar
27.
Maumenee  AE Retrobulbar alcohol injections; relief of ocular pain in eyes with and without vision.  Am J Ophthalmol 1949;32 (11) 1502- 1508PubMedGoogle Scholar
28.
al-Faran  MFal-Omar  OM Retrobulbar alcohol injection in blind painful eyes.  Ann Ophthalmol 1990;22 (12) 460- 462PubMedGoogle Scholar
29.
Kumar  CMDowd  TCHawthorne  M Retrobulbar alcohol injection for orbital pain relief under difficult circumstances: a case report.  Ann Acad Med Singapore 2006;35 (4) 260- 265PubMedGoogle Scholar
30.
Custer  PLReistad  CE Enucleation of blind, painful eyes.  Ophthal Plast Reconstr Surg 2000;16 (5) 326- 329PubMedGoogle Scholar
31.
Mermoud  ASalmon  JFAlexander  PStraker  CMurray  AD Molteno tube implantation for neovascular glaucoma: long-term results and factors influencing the outcome.  Ophthalmology 1993;100 (6) 897- 902PubMedGoogle Scholar
32.
Pastor  SASingh  KLee  DA  et al.  Cyclophotocoagulation: a report by the American Academy of Ophthalmology.  Ophthalmology 2001;108 (11) 2130- 2138PubMedGoogle Scholar
33.
Bates  DOCurry  FE Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway.  Am J Physiol 1997;273 (2 pt 2) H687- H694PubMedGoogle Scholar
34.
Carmeliet  P Angiogenesis in health and disease.  Nat Med 2003;9 (6) 653- 660PubMedGoogle Scholar
35.
Penn  JSMadan  ACaldwell  RBBartoli  MCaldwell  RWHartnett  ME Vascular endothelial growth factor in eye disease.  Prog Retin Eye Res 2008;27 (4) 331- 371PubMedGoogle Scholar
36.
Yazdani  SHendi  KPakravan  M Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.  J Glaucoma 2007;16 (5) 437- 439PubMedGoogle Scholar
37.
Mason  JO  IIIAlbert  MA  JrMays  AVail  R Regression of neovascular iris vessels by intravitreal injection of bevacizumab.  Retina 2006;26 (7) 839- 841PubMedGoogle Scholar
38.
Eid  TMRadwan  Ael-Manawy  Wel-Hawary  I Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy.  Can J Ophthalmol 2009;44 (4) 451- 456PubMedGoogle Scholar
39.
Takihara  YInatani  MFukushima  M  et al.  Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.  Am J Ophthalmol 2009;147912- 918Google Scholar
40.
Chen  CHLai  ICWu  PC  et al.  Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma.  J Ocul Pharmacol Ther 2010;26 (1) 111- 118PubMedGoogle Scholar
41.
Elgin  UBerker  NBatman  ASimsek  TCankaya  B Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.  J Glaucoma 2006;15 (5) 466- 470PubMedGoogle Scholar
42.
Saito  YHigashide  TTakeda  H  et al.  Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma.  Acta Ophthalmol 2010;88 (1) 96-- 102PubMedGoogle Scholar
43.
Alkawas  AAShahien  EAHussein  AM Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C [published online ahead of print February 22, 2010].  J Glaucoma 2010;19 (9) 622- 626PubMed10.1097/IJG.0b013e3181ccb794Google Scholar
44.
Bartz-Schmidt  KUThumann  GPsichias  AKrieglstein  GKHeimann  K Pars plana vitrectomy, endolaser coagulation of the retina and the ciliary body combined with silicone oil endotamponade in the treatment of uncontrolled neovascular glaucoma.  Graefes Arch Clin Exp Ophthalmol 1999;237 (12) 969- 975PubMedGoogle Scholar
45.
Kiuchi  YNakae  KSaito  YIto  SIto  N Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma.  Graefes Arch Clin Exp Ophthalmol 2006;244 (12) 1627- 1632PubMedGoogle Scholar
46.
Inan  UUAvci  BKusbeci  TKaderli  BAvci  RTemel  SG Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.  Invest Ophthalmol Vis Sci 2007;48 (4) 1773- 1781PubMedGoogle Scholar
47.
Beutel  JPeters  SLuke  M  et al.  Bevacizumab as adjuvant for neovascular glaucoma.  Acta Ophthalmol 2010;88 (1) 103- 109PubMedGoogle Scholar
48.
Jiang  YLiang  XLi  XTao  YWang  K Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.  Acta Ophthalmol 2009;87 (7) 736- 740PubMedGoogle Scholar
49.
Hasanreisoglu  MWeinberger  DMimouni  K  et al.  Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma.  Eur J Ophthalmol 2009;19 (4) 607- 612PubMedGoogle Scholar
50.
Yazdani  SHendi  KPakravan  MMahdavi  MYaseri  M Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.  J Glaucoma 2009;18 (8) 632- 637PubMedGoogle Scholar
51.
Georgopoulos  MPolak  KPrager  FPrünte  CSchmidt-Erfurth  U Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).  Br J Ophthalmol 2009;93 (4) 457- 462PubMedGoogle Scholar
52.
Gillies  MC What we don't know about Avastin might hurt us.  Arch Ophthalmol 2006;124 (10) 1478- 1479PubMedGoogle Scholar
53.
Fung  AERosenfeld  PJReichel  E The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide.  Br J Ophthalmol 2006;90 (11) 1344- 1349PubMedGoogle Scholar
Clinical Sciences
February 14, 2011

Intravitreal Bevacizumab in Refractory Neovascular Glaucoma: A Prospective, Observational Case Series

Author Affiliations

Author Affiliations: National Institute for Health Research Biomedical Research Centre for Ophthalmology (Dr Kotecha), Glaucoma Research Unit (Drs Kotecha, Spratt, Ogunbowale, dell’Omo, Kulkarni, and Franks), and Research Department (Dr Bunce), Moorfields Eye Hospital NHS Foundation Trust; and Department of Optometry, The City University (Dr Kotecha), London, England.

Arch Ophthalmol. 2011;129(2):145-150. doi:10.1001/archophthalmol.2010.350
Abstract

Objective  To examine the efficacy of intravitreal bevacizumab for pain relief in eyes with refractory neovascular glaucoma.

Methods  In this prospective case series, 52 eyes with neovascular glaucoma were administered intravitreal bevacizumab, 1.25 mg, and monitored for 6 months. The primary outcome measure was change in subjective pain score. Intraocular pressure and iris neovascularization were evaluated at each visit. Surgical intervention for control of intraocular pressure was performed according to clinical need.

Results  Forty-two patients (44 eyes) completed the 6-month follow-up. Subjective pain score was reduced significantly 1 week after intravitreal bevacizumab injection and lasted throughout the follow-up period (median [interquartile range]: baseline, 3 [0-6]; week 1, 1 [0-3]; month 1, 0 [0-1]; month 3, 0 [0-1]; and month 6, 0 [0-0]; Kruskal-Wallis χ2 31.03; P < .001). A rapid, yet relatively transient, reduction in iris neovascularization was also noted (iris neovascularization grade at baseline, 4.0 [3-4]; week 1, 2.5 [1-4]; month 1, 2.0 [1-4]; month 3, 3.0 [2-4]; and month 6, 3.0 [2-4], χ2 23.33; P < .001). Four eyes (8%) required more than 1 injection to facilitate further intraocular surgery.

Conclusions  Intravitreal bevacizumab is a useful adjunct in the management of refractory neovascular glaucoma, producing rapid relief of pain. However, we found no evidence to suggest that intravitreal bevacizumab lowers intraocular pressure in eyes with angle closure; conventional medical, laser, and surgical treatment are still needed in these eyes.

×